Diagnostic value of serum NSE, and S-100β and inflammatory markers levels in epilepsy.

IF 1.9 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2026-02-27 DOI:10.5937/jomb0-55343

Zhaoxia Li, Li Su, Yi Lu, Yunqing Hu, Qian Yang

{"title":"Diagnostic value of serum NSE, and S-100β and inflammatory markers levels in epilepsy.","authors":"Zhaoxia Li, Li Su, Yi Lu, Yunqing Hu, Qian Yang","doi":"10.5937/jomb0-55343","DOIUrl":null,"url":null,"abstract":"Background: To sodium valproate lore the effects of sodium valproate on serum inflammatory factors and s-100β levels in patients with emergency secondary epilepsy(SE).Methods: This was a retrospective cohort of 120 patients with SE who received Sodium valproate compared with a group who received carbamazepine for different therapeutic drugs. The general data, interleukin (IL)-2, IL-8, tumour necrosis factor (TNF)-α, neuron-specific enolase (NSE), serum acid calcium-binding protein s-100β, total effective rate (TER), seizure onset condition, and adverse reactions (Ars) of the two groups were compared at baseline and at 3 months later.Results: There were no significant differences in age, gender, BMI, course of the disease, stroke type, or seizure type between the study groups (P> 0.05). The results showed that IL-2 of the Sodium valproate group (53.17± 4.95 μg/L) was lower versus Carbamazepine group (62.38± 4.83 μg/L) (P< 0.05). The IL-8 of the Sodium valproate group postoperatively (26.48± 2.73 μg/L) was lower versus the Carbamazepine group (33.54± 3.39 μg/L) (P< 0.05). Postoperatively, the TNF-α in Sodium valproate group (32.18± 4.26 μg/L) was lower versus the Carbamazepine group (41.03± 4.92 μg/L) (P< 0.05). The s-100β (0.29 ± 0.15 ) μg/L in the Sodium valproate group was lower versus the Carbamazepine group (0.54± 0.14) μg/L (P < 0.05). The TER of the Sodium valproate group (93.33% ) was higher versus the Carbamazepine group of 75% (P < 0 .0 5 ). The number of epileptic seizures in the Sodium valproate group was 0.81± 0.08 times per year versus 1.23± 0.12 times per year in the Carbamazepine group. The duration of epilepsy in the Sodium valproate group (2.53± 0.22 min/time) was shorter than that in the Carbamazepine group (3.08 ± 0.24 min/time).Conclusions: Sodium valproate can drastically relieve the epileptic symptoms of patients with SE, and there was no great difference in ARs. Hence, it is safe and worthy of popularization and application.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"45 2","pages":"422-428"},"PeriodicalIF":1.9000,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-55343","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To sodium valproate lore the effects of sodium valproate on serum inflammatory factors and s-100β levels in patients with emergency secondary epilepsy(SE).

Methods: This was a retrospective cohort of 120 patients with SE who received Sodium valproate compared with a group who received carbamazepine for different therapeutic drugs. The general data, interleukin (IL)-2, IL-8, tumour necrosis factor (TNF)-α, neuron-specific enolase (NSE), serum acid calcium-binding protein s-100β, total effective rate (TER), seizure onset condition, and adverse reactions (Ars) of the two groups were compared at baseline and at 3 months later.

Results: There were no significant differences in age, gender, BMI, course of the disease, stroke type, or seizure type between the study groups (P> 0.05). The results showed that IL-2 of the Sodium valproate group (53.17± 4.95 μg/L) was lower versus Carbamazepine group (62.38± 4.83 μg/L) (P< 0.05). The IL-8 of the Sodium valproate group postoperatively (26.48± 2.73 μg/L) was lower versus the Carbamazepine group (33.54± 3.39 μg/L) (P< 0.05). Postoperatively, the TNF-α in Sodium valproate group (32.18± 4.26 μg/L) was lower versus the Carbamazepine group (41.03± 4.92 μg/L) (P< 0.05). The s-100β (0.29 ± 0.15 ) μg/L in the Sodium valproate group was lower versus the Carbamazepine group (0.54± 0.14) μg/L (P < 0.05). The TER of the Sodium valproate group (93.33% ) was higher versus the Carbamazepine group of 75% (P < 0 .0 5 ). The number of epileptic seizures in the Sodium valproate group was 0.81± 0.08 times per year versus 1.23± 0.12 times per year in the Carbamazepine group. The duration of epilepsy in the Sodium valproate group (2.53± 0.22 min/time) was shorter than that in the Carbamazepine group (3.08 ± 0.24 min/time).

Conclusions: Sodium valproate can drastically relieve the epileptic symptoms of patients with SE, and there was no great difference in ARs. Hence, it is safe and worthy of popularization and application.

查看原文本刊更多论文

血清NSE、S-100β及炎症标志物水平对癫痫的诊断价值。

背景：探讨丙戊酸钠对急诊继发性癫痫（SE）患者血清炎症因子及s-100β水平的影响。方法：对120例接受丙戊酸钠治疗的SE患者与接受卡马西平治疗的SE患者进行回顾性队列研究。比较两组患者基线及3个月后的一般数据、白细胞介素(IL)-2、IL-8、肿瘤坏死因子(TNF)-α、神经元特异性烯醇化酶（NSE）、血清酸性钙结合蛋白s-100β、总有效率（TER）、癫痫发作情况、不良反应（Ars）。结果：两组患者在年龄、性别、BMI、病程、脑卒中类型、癫痫发作类型等方面无显著差异（P> 0.05）。结果显示，丙戊酸钠组IL-2（53.17±4.95 μg/L）低于卡马西平组（62.38±4.83 μg/L）（P< 0.05）。丙戊酸钠组术后IL-8水平（26.48±2.73 μg/L）低于卡马西平组（33.54±3.39 μg/L）（p < 0.05）。术后丙戊酸钠组TNF-α（32.18±4.26 μg/L）低于卡马西平组（41.03±4.92 μg/L）（p < 0.05）。丙戊酸钠组s-100β含量（0.29±0.15）μg/L低于卡马西平组（0.54±0.14）μg/L （P < 0.05）。丙戊酸钠组TER（93.33%）高于卡马西平组（75%）(P <；5)。丙戊酸钠组癫痫发作次数为每年0.81±0.08次，卡马西平组为每年1.23±0.12次。丙戊酸钠组癫痫持续时间（2.53±0.22 min/time）短于卡马西平组（3.08±0.24 min/time）。结论：丙戊酸钠能显著缓解SE患者的癫痫症状，而ar的差异无统计学意义。因此，它是安全的，值得推广应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.